Alpa Laboratories (ALPA) | Financial Analysis & Statements
Alpa Laboratories Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
191.1M
Gross Profit
64.2M
33.62%
Operating Income
-1.3M
-0.68%
Net Income
117.7M
61.58%
EPS (Diluted)
₹5.59
Balance Sheet Metrics
Total Assets
2.2B
Total Liabilities
511.9M
Shareholders Equity
1.7B
Debt to Equity
0.30
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Alpa Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 924.1M | 1.1B | 964.1M |
| Cost of Goods Sold | 760.4M | 746.0M | 615.0M | 760.9M | 647.6M |
| Gross Profit | 355.9M | 333.1M | 309.1M | 344.3M | 316.6M |
| Gross Margin % | 31.9% | 30.9% | 33.5% | 31.2% | 32.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 97.5M | 75.2M | 62.6M | 75.2M | 66.9M |
| Other Operating Expenses | 65.1M | 35.4M | 42.7M | 54.5M | 33.4M |
| Total Operating Expenses | 162.7M | 110.6M | 105.3M | 129.6M | 100.3M |
| Operating Income | 34.5M | 77.3M | 73.4M | 95.4M | 97.2M |
| Operating Margin % | 3.1% | 7.2% | 7.9% | 8.6% | 10.1% |
| Non-Operating Items | |||||
| Interest Income | 20.4M | 23.2M | 10.4M | 14.6M | 6.5M |
| Interest Expense | 291.0K | 3.2M | 825.0K | 1.1M | 261.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 256.7M | 206.8M | 158.9M | 195.6M | 107.9M |
| Income Tax | 61.6M | 39.1M | 33.1M | 54.7M | 35.4M |
| Effective Tax Rate % | 24.0% | 18.9% | 20.8% | 28.0% | 32.8% |
| Net Income | 195.0M | 167.8M | 125.8M | 140.9M | 72.5M |
| Net Margin % | 17.5% | 15.5% | 13.6% | 12.8% | 7.5% |
| Key Metrics | |||||
| EBITDA | 90.2M | 143.3M | 146.2M | 130.3M | 112.5M |
| EPS (Basic) | ₹9.27 | ₹8.01 | ₹5.88 | ₹6.70 | ₹3.45 |
| EPS (Diluted) | ₹9.27 | ₹8.01 | ₹5.88 | ₹6.70 | ₹3.45 |
| Basic Shares Outstanding | 21040600 | 21040600 | 21040600 | 21040600 | 21041000 |
| Diluted Shares Outstanding | 21040600 | 21040600 | 21040600 | 21040600 | 21041000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Alpa Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 22.2M | 17.1M | 88.1M | 15.8M | 18.0M |
| Short-term Investments | 1.1B | 911.4M | 720.3M | 687.0M | 406.9M |
| Accounts Receivable | 468.3M | 411.5M | 467.3M | 380.4M | 354.3M |
| Inventory | 176.4M | 136.7M | 126.4M | 154.6M | 165.6M |
| Other Current Assets | 3.2M | 667.0K | 81.6M | 72.7M | 107.8M |
| Total Current Assets | 1.9B | 1.6B | 1.5B | 1.4B | 1.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 61.2M | 58.6M | 58.3M | 58.2M | 58.2M |
| Goodwill | 483.0K | 601.0K | 834.0K | 2.1M | 1.1M |
| Intangible Assets | 483.0K | 601.0K | 834.0K | 1.0M | 551.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 301.4M | 213.9M | 173.9M | 172.3M | 192.8M |
| Total Assets | 2.2B | 1.8B | 1.6B | 1.6B | 1.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 186.9M | 117.8M | 150.6M | 149.2M | 247.3M |
| Short-term Debt | 343.0K | 52.5M | 15.3M | 37.2M | 1.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 213.6M | 78.3M | 22.8M | 25.7M | 2.8M |
| Total Current Liabilities | 467.0M | 280.7M | 296.3M | 313.8M | 327.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 0 | 0 | 7.8M | 21.2M | 91.0K |
| Deferred Tax Liabilities | 44.9M | 24.0M | 22.8M | 25.7M | 2.2M |
| Other Non-Current Liabilities | - | -1.0K | 1.0K | -2.0K | 1.0K |
| Total Non-Current Liabilities | 44.9M | 24.0M | 30.6M | 21.2M | 92.0K |
| Total Liabilities | 511.9M | 304.6M | 326.9M | 335.1M | 327.3M |
| Equity | |||||
| Common Stock | 210.4M | 210.4M | 210.4M | 210.4M | 210.4M |
| Retained Earnings | 954.3M | 759.1M | 585.8M | 457.3M | 316.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.7B | 1.5B | 1.3B | 1.2B | 1.1B |
| Key Metrics | |||||
| Total Debt | 343.0K | 52.5M | 23.0M | 58.5M | 1.9M |
| Working Capital | 1.5B | 1.3B | 1.2B | 1.1B | 883.7M |
Balance Sheet Composition
Alpa Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 258.2M | 207.6M | 156.8M | 195.6M | 107.9M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -121.9M | 42.3M | -38.2M | 86.8M | -225.2M |
| Operating Cash Flow | 11.7M | 235.1M | 110.4M | 270.0M | -123.0M |
| Investing Activities | |||||
| Capital Expenditures | -113.8M | -63.9M | -11.3M | -21.9M | -28.5M |
| Acquisitions | 112.6M | 0 | -5.0M | 42.3M | 0 |
| Investment Purchases | -33.9M | -95.1M | -286.0K | -191.8M | - |
| Investment Sales | - | - | - | - | 79.1M |
| Investing Cash Flow | -35.1M | -159.0M | 9.0M | -171.4M | 50.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | 4.5M |
| Debt Repayment | - | - | -263.0K | - | -1.8M |
| Financing Cash Flow | -52.5M | 37.2M | -525.0K | 58.5M | 5.2M |
| Free Cash Flow | -43.2M | -27.4M | 77.8M | 77.5M | -49.2M |
| Net Change in Cash | -75.9M | 113.3M | 118.9M | 157.1M | -67.1M |
Cash Flow Trend
Alpa Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.42
Forward P/E
12.96
Price to Book
0.84
Price to Sales
1.26
PEG Ratio
-0.16
Profitability Ratios
Profit Margin
10.15%
Operating Margin
2.97%
Return on Equity
11.38%
Return on Assets
8.76%
Financial Health
Current Ratio
4.16
Debt to Equity
0.00
Beta
0.76
Per Share Data
EPS (TTM)
₹5.52
Book Value per Share
₹81.47
Revenue per Share
₹54.35
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALPA | 1.4B | 12.42 | 0.84 | 11.38% | 10.15% | 0.00 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





